Oxalic Acid

Oxalic Acid

SCHEMBL6773628

Brc1ccc2[nH]cc(CCN3CCN(c4cccc5c4OCCO5)CC3)c2c1.O=C(O)C(=O)O

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 16/20 0.69
HTR7 P34969 1/20 0.50
HTR1A P08908 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6589123 0.95 DRD2 (0.77) DRD2HTR1A
Oxalic Acid SCHEMBL6595691 0.90 DRD2 (0.81) DRD2HTR1A
Oxalic Acid SCHEMBL6590606 0.90 DRD2 (0.81) DRD2HTR7HTR1A
SCHEMBL6592003 0.84 DRD2 (0.89) DRD2
SCHEMBL6591394 0.84 DRD2 (0.89) DRD2HTR7HTR1A
SCHEMBL6589929 0.84 DRD2 (0.89) DRD2HTR1A
SCHEMBL6589414 0.82 DRD2 (1.00) DRD2HTR1A
SCHEMBL6590679 0.81 DRD2 (0.90) DRD2HTR1A
SCHEMBL6108416 0.81 DRD2 (0.73) DRD2HTR1A
Oxalic Acid SCHEMBL6592440 0.81 DRD2 (0.80) DRD2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1515569-A Indole and 2,3-indoline derivative, their preparation and application H.隆德贝克有限公司 2004-07-28 CN disclosed
CN-1515568-A Indole and 2,3-indoline derivative, their preparation and application H.隆德贝克有限公司 2004-07-28 CN disclosed
US-6727263-B2 SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION H. LUNDBECK A/S (DK) 2004-04-27 US disclosed
CN-1127501-C indole and 2, 3-indoline derivatives, their preparation and use LUNDBECK & CO AS H (DK) 2003-11-12 CN disclosed
US-20030018050-A1 Indole and 2,3-dihydroindole derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-01-23 US disclosed
US-6476035-B1 Indole and 2,3-dihydroindole derivatives, their preparation and use H. LUNDBECK A/S (DK) 2002-11-05 US disclosed
CN-1265107-A indole and 2, 3-indoline derivatives, their preparation and use LUNDBECK & CO AS H (DK) 2000-08-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018050-A1 Indole and 2,3-dihydroindole derivatives, their preparation and use TPH1, HTR1A, HTR3A DRD2 26/4885HTR7 16/4885HTR1A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.